Rivaroxaban
Deep Venous Thrombosis
Hospital do Servidor Publico EstadualSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Deep Venous Thrombosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enoxaparin University Of Perugia | Phase 3 | BBB |
WARFARIN Sanford Health | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II University Of Perugia | Phase 3 | BB |
FLUOROURACILUM University Of Perugia | Phase 3 | BB |
Calcium folinate pentahydrate University Of Perugia | Phase 3 | BB |
HEPARIN Johns Hopkins University | Phase 4 | B |
Apixaban Sanford Health | Phase 2/3 | B |
FONDAPARINUX Johns Hopkins University | Early Phase 1 | CC |
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →